Parikshit Somani Banned for Four Years: Trimetazidine, the Contamination Defence and the Shadow of Kamila Valieva

When the International Tennis Integrity Agency (ITIA) announced the sanction against Parikshit Somani, no press conference was called in London. Just a statement. A few lines about a 26-year-old Indian player, career-high doubles ranking of 256, who tested positive for trimetazidine at a lower-tier event in Astana, Kazakhstan. An independent tribunal banned him until September 2029.

Four years. For a player outside the doubles top 200, four years is not a break between seasons. It is almost the entire remaining span of a professional career. During the suspension he cannot play, coach at, or attend any event organised by World Tennis, the WTA, the ATP, the Grand Slams or any national federation.

People look at the ranking; I look at what the ranking hides. The ranking tells me Somani was never a name on television. It does not tell me that behind that four-year sentence sits a man in front of a tribunal, trying to explain that the prohibited substance entered his body through a meal cooked by a family member — and failing.

According to the ITIA, at an August hearing Somani's defence did not prove the source of the alleged contamination. The tribunal concluded that the food contamination theories were "scientifically implausible", "highly speculative" and "unconvincing". That is the language of a panel that has heard the same story too many times.

A heart pill that crosses four sports

Trimetazidine is not unfamiliar to anyone who follows international doping cases. It is an angina medication that works by partially inhibiting fatty acid oxidation in the mitochondria, pushing the heart muscle towards glucose oxidation — a pathway that consumes less oxygen to produce the same energy. For a patient with narrowed coronary arteries, that is a medical benefit. For an endurance athlete, it is an attractive theory: with the same oxygen, the body does more work.

The substance has been on the WADA prohibited list since 1 January 2026, in class S4 — hormone and metabolic modulators. Over more than a decade, trimetazidine has been one of the most recurrent molecules in high-profile cases. Every time it appears, it drags along a different story about origin — and every story must pass through the same narrow door of evidence.

Sun Yang opened that sequence. The Chinese swimmer tested positive in May 2026 and received a three-month ban, explaining that he had been using the medication for heart palpitations for years and did not know the substance had just been added to the list. The ban was only widely reported in November of that year, after journalists found it. Three months for a substance with no threshold. Four years for Kamila Valieva in Beijing 2026. And now four years for a doubles player ranked 256.

Valieva shaped how the public reads every trimetazidine case that followed. Her sample was collected at the Russian national championships in December 2026, weeks before she became the face of figure skating at the Winter Olympics. Only on 29 January 2026 did the Court of Arbitration for Sport publish the final ruling: a four-year ban running from 25 December 2026, with all results from that date annulled. The argument her lawyers advanced — that the substance came from a dessert prepared by her grandfather — was rejected.

The common ground between Valieva and Somani is not the sport, the age or the ranking. It is the shape of the defence: a prohibited substance entering the body through food prepared by a family member. The same substance. The same structure of argument. The same four-year outcome.

The evidence trap

Reading the ITIA statement, I lingered on the three adjectives the tribunal used for Somani's explanation. Those three words contain the entire architecture of modern anti-doping law.

The founding principle is strict liability: an athlete is responsible for everything in their body, regardless of intent. The anti-doping authority does not need to prove you meant it. The burden shifts entirely to the athlete, and it splits into two layers. First: prove how the substance entered the body. Second: prove no significant fault or no fault at all, under Articles 10.5 and 10.6 of the World Anti-Doping Code.

The first layer is the hardest, and it is where both Somani and Valieva fell. Saying "my relative's medicine got into the food" is only a hypothesis. Turning a hypothesis into evidence requires an unbroken data chain: the relative's prescription, the date of use, the active content of the pill, the cooking method, the temperature, absorption through the digestive tract, and above all whether the concentration of metabolites in the urine sample is compatible with the alleged dose.

Without that chain, the panel is left with one question: is this pathway more likely than not to have happened? That is the standard, and it does not indulge beautiful stories.

The crux is that trimetazidine has no technical decision limit: detection of the parent drug or its metabolite is enough to open proceedings, which means there is no grey zone for an extremely low result. There are only two outcomes. Either it is contamination and you can prove it, or it is a positive. Between those outcomes, for a 26-year-old without a sports law team behind him, the distance is measured in four years.

I have an old habit from my early years in the job: whenever a doping ruling is published, I read every comparable case before writing a line. Some data does not need to be loud, it only needs someone patient enough to read it. Read four cases in a row — Sun Yang 2026, Maria Sharapova 2026 with meldonium, a metabolic modulator in the same S4 class whose two-year ban was cut to fifteen months on appeal, Valieva 2026 and Somani — and what emerges is not the moral story of individuals but a repeating technical pattern: substances that act on energy metabolism, defences about contamination from the home, and support systems too thin to prove anything.

Based on my experience following hearings and matches across many levels of the sport, I have found that the quality of a defence rarely depends on whether the athlete is telling the truth. It depends on whether the athlete kept records.

The economics of events without spectators

To understand how a doubles player ranked 256 ends up here, you have to look at the economic structure of the system he plays in. Lower-tier professional events — the kind where Somani was tested in Astana — operate with prize money at a level that forces a player to split costs for travel, hotels, food and a coach. At that level there is no team doctor, no nutritionist, no sports lawyer standing behind you.

Yet at that same level, the testing regime applies the same code, the same standard and the same sanction range as at the very top of the sport. A player ranked 256 in doubles carries strict liability equal to a top-10 player. That equality sounds fair on paper, and it genuinely is fair in principle, because it protects clean athletes. It is not fair in resources.

This is the point I always want readers to see: the anti-doping system invests most of its budget in detection, and far less in education and support. For players at the lower tiers, checking the prohibited list before taking a cold tablet is a habit nobody ever taught them. By the time it becomes a problem, they are already in a hearing room.

The counter-reading

There is a contrarian reading I believe is correct, even if it is uncomfortable.

The current system has only one instrument for expressing severity, and that instrument is time. The result is that situations with very different levels of culpability — an athlete poisoned by a relative, an athlete who took the wrong pill, an athlete who actively sought a chemical edge — all receive the same four-year frame when the substance is not a specified substance. That uniformity has a technical justification: when nothing can be proven, the panel has no basis for distinction. But the consequence is that the system equates ignorance with deceit, and four years for a player outside the top 200 is a career-ending sentence that never says so out loud.

Another counter-reading runs the opposite way: every failed contamination defence erodes the value of an honest one. Somani and Valieva may have told the truth, or may not have. But after cases like these, a young player in Da Nang whose father's medicine genuinely did get into dinner will face a panel that is wearier, more suspicious and less patient. That is the price the innocent pay for what others have tried, even once.

Elite sport is the art of repetition — and of breaking repetition. The cycle of testing and hearings works the same way: it repeats long enough to become procedure, then a single case breaks the procedure with a new argument, and the whole system has to learn to read itself again.

What I want young writers and young players to carry

If there is one concrete lesson from the Somani case, it is not in the verdict. It is in the period before the verdict.

Any player competing at the lower tiers should keep a simple medical ledger: photographs of every prescription in the household, purchase dates, expiry dates, active ingredient names, and a line noting who at home takes what. It sounds fussy. But when a urine sample becomes a problem, that ledger is the only thing that turns a story into a file. Without it, the athlete has only a narrative, and tribunals do not work with narratives.

I would also say this to young writers covering cases like this one: do not turn every ruling into a tidy morality tale. Somewhere a 26-year-old has just lost four years of a career, and a scientific process was never designed for his circumstances. Both things are true at once.

Professional tennis has more than two thousand singles players alone, plus thousands of doubles players scraping by at the lower tiers, where prize money does not cover a single at-home blood test. In a system like that, the only way a small player protects himself is by documenting more than anyone thinks necessary, and reading the prohibited list more often than anyone thinks sufficient.

The line between a pitiable accident and a four-year sentence will be decided by the smallest details: a photograph of a pill box, a date in a notebook, a ledger left on the kitchen table. That is the kind of data nobody hands out trophies for, and it is the only thing standing between a person and the rest of a career.